NewTimeSpace News, as of 10:37 on March 17, 2026, Innovative Medicine ETF (515120) rose 1.83%, with the latest price at 0.61 yuan. Looking at a longer time frame, as of March 16, 2026, Innovative Medicine ETF has cumulatively gained 1.52% over the past week. (The stocks listed above are index constituents only and do not represent specific recommendations.)

In terms of liquidity, Innovative Medicine ETF recorded a turnover rate of 2.14% intraday, with trading volume reaching 188 million yuan. Looking at a longer time frame, as of March 16, the average daily trading volume over the past year was 265 million yuan, ranking among the top 2 comparable funds.

In terms of scale, Innovative Medicine ETF has grown by 45.7731 million yuan over the past week, achieving significant growth and ranking 1st among 7 comparable funds in terms of new scale additions. (Data Source: Wind)

In terms of shares, Innovative Medicine ETF has reached 14.456 billion shares most recently, hitting a new high for the past month and ranking 2nd among 7 comparable funds. (Data Source: Wind)

Regarding capital inflows, Innovative Medicine ETF has recorded consecutive net capital inflows for the past 4 days, with a maximum single-day net inflow of 80.5059 million yuan, totaling 172 million yuan in "capital attraction," with an average daily net inflow of 43.012 million yuan. (Data Source: Wind)

Data shows that leveraged funds continue to build positions. Innovative Medicine ETF has seen net buying from leveraged funds for 4 consecutive days, with a maximum single-day net purchase of 10.241 million yuan, and the latest financing balance reaching 335 million yuan. (Data Source: Wind)

As of March 16, Innovative Medicine ETF has risen 8.66% in net asset value over the past 2 years. In terms of return capability, as of March 16, 2026, since its inception, Innovative Medicine ETF has achieved a maximum monthly return of 23.00%, a longest consecutive rising streak of 5 months, a maximum consecutive gain of 32.68%, and an average return of 5.63% during rising months. As of March 16, 2026, the annualized excess return over the benchmark for the past 2 years is 0.82%.

In terms of drawdown, as of March 16, 2026, the relative benchmark drawdown of Innovative Medicine ETF year-to-date is 0.08%.

In terms of fees, Innovative Medicine ETF has a management fee of 0.50% and a custody fee of 0.10%.

Regarding tracking accuracy, as of March 16, 2026, the 6-month tracking error of Innovative Medicine ETF is 0.012%, representing the highest tracking accuracy among comparable funds.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by Innovative Medicine ETF has a latest price-to-earnings ratio (PE-TTM) of only 47.77x, at the 13.69th percentile over the past year, meaning the valuation is lower than 86.31% of the time over the past year, placing it at a historical low.

Innovative Medicine ETF closely tracks the CSI Innovative Medicine Industry Index. The CSI Innovative Medicine Industry Index selects up to 50 most representative securities from listed companies whose main business involves innovative drug research and development as index samples, aiming to reflect the overall performance of securities of listed companies in the innovative medicine industry.

On the news front, positive developments at the industry level have been densely implemented. In the first two months of 2026, Chinese innovative drug BD amount has already reached $53.276 billion, with the overseas expansion momentum continuing high growth. The government work report from the Two Sessions for the first time listed biomedical as an emerging pillar industry, significantly elevating the industry's strategic status.

Industrial Securities stated that innovative drug overseas expansion has entered the implementation stage, with clinical progress following BD transactions continuing to catalyze valuation enhancement. Policy explicitly supports biomedical as an emerging pillar industry. Domestic innovative drug enterprises have established efficiency and cost advantages in global frontier technology fields such as ADC and bispecific antibodies, with the industry entering the 3.0 era.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.